A Clinical Study to Evaluate the Efficacy and Safety of Monopolar Radiofrequency Combined With SkinCeuticals A.G.E and Skinceuticals CE FERULIC for Improving Facial Skin Elasticity, Tightening and Fading Fine Lines
Launched by YES SKIN MEDICAL GROUP · Jan 18, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new treatment to help improve the appearance of aging skin on the face. Specifically, it is studying the effects of a procedure called monopolar radiofrequency combined with two skincare products, SkinCeuticals A.G.E and CE FERULIC. The goal is to see if this treatment can make the skin tighter, more elastic, and help reduce fine lines that often appear as we age.
To participate in this study, women aged 25 to 65 who have noticeable signs of aging, like loose skin and fine lines, may be eligible. Participants should be generally healthy and willing to avoid certain cosmetics and medications during the trial. If you join, you'll receive the treatment on one side of your face while the other side is used for comparison. Throughout the study, you'll be asked to follow some simple guidelines to help ensure accurate results. This trial is still in the planning stages, and they have not started recruiting participants yet.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- * Subjects must meet all of the following criteria to be enrolled in the study:
- • 1. Healthy women, skin quality is not limited, aged 25 \~ 65 years old face old \~ moderate aging group;
- • 2. subjects facial skin rough, loose, lack of elasticity;
- • 3. Subjects with multiple facial fine lines, decree lines or puppet lines areas have static fine lines trend, the lower part showed signs of loosening;
- • 4. Subjects with consistent facial skin status on both sides and planning to receive monopolar radiofrequency treatment;
- • 5. Be able to cooperate well with the tester and maintain the regularity of life during the study;
- • 6. Be able to read and understand all contents of the informed consent form, and voluntarily sign the informed consent form (ICF);
- • 7. Agreed not to use any cosmetics, drugs and health products that have an impact on the results during the trial;
- Exclusion Criteria:
- * Subjects were not included in the study if they met any of the following exclusion criteria:
- • 1. Subjects with contraindications to monopolar radiofrequency treatment (such as malignant tumors, acute systemic infection, metal implants or active implants in the body such as cardiac pacemakers/defibrillators, etc.) or contraindications to A.G.E./CE use (or allergies to other skin care components);
- • 2. Subjects with facial skin diseases, infections, inflammation, etc. that may affect the judgment of the test results;
- • 3. Subjects with hypertrophic scar or scar constitution;
- • 4. Subjects who have experienced tightening medical treatment (Gemma, Fotona 4D, ultrasonic cannon, ultrasonic scalpel, gold microneedle, etc.) in the past 3 months;
- • 5. Subjects who have oral and topical cosmetic products that may affect the study results within 2 weeks;
- • 6. Subjects who participate in drug clinical trials or other trials within 30 days, or subjects who have systemic use of drugs that may affect the study results within the past 1 week;
- • 7. Pregnant or lactating women, or recent plans to prepare for pregnancy;
- • 8. Other subjects who are not suitable for participating in this study as assessed by the investigator.
About Yes Skin Medical Group
Yes Skin Medical Group is a leading clinical trial sponsor specializing in innovative dermatological treatments and procedures. Committed to advancing skin health, the organization conducts rigorous clinical research to evaluate the efficacy and safety of new therapies. With a team of experienced professionals and a patient-centered approach, Yes Skin Medical Group collaborates with researchers and healthcare providers to ensure high standards of compliance and ethical conduct in all trials. Their dedication to scientific excellence and patient care positions them at the forefront of dermatological advancements, contributing to improved outcomes for individuals with various skin conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported